Low high-density lipoprotein cholesterol disorders and cardiovascular risk: Contribution of associated low-density lipoprotein subclass abnormalities

Current Opinion in Cardiology

Volumn 20, Issue 4, 2005, Pages 313-317

  Rosenson, Robert S ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cardiovascular risk; Coronary heart disease risk; High density lipoprotein; Low density lipoprotein; Low density lipoprotein subclasses

Indexed keywords

ATORVASTATIN; ETC 216; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; TORCETRAPIB;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG TARGETING; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; META ANALYSIS; MOLECULAR INTERACTION; ONSET AGE; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; VASCULAR DISEASE;

ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; GEMFIBROZIL; HUMANS; LIPOPROTEINS, LDL; LOVASTATIN; RISK FACTORS; SIMVASTATIN;

EID: 21244443438     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000168534.15085.5d     Document Type: Review

References (44)

1. Expert Panel on Detection E. and Treatment of High Blood Cholesterol in Adults, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
2. Haffner SM. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27 (suppl 1):S68-S71.
3. Gotto AM, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease. J Am Coll Cardiol 2004; 43:717-724.
4. Rosenson RS. Low HDL-C: a secondary target of dyslipidemia therapy. Am J Med 2005. (in press).
5. Hill SA, McQueen MJ. Reverse cholesterol transport - a review of the process and its clinical implications. Clin Biochem 1997; 30:517-525.
6. Kontush A, de Faria EC, Chantepie S, Chapman MJ. Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties. Arterioscler Thromb Vasc Biol 2004; 24:526-533.
7. Navab M, Hama SY, Cooke CJ, et al. Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low-density lipoprotein steps 1. J Lipid Res 2000; 41:1481-1494.
8. Navab M, Hama SY, Anantharamaiah GM, et al. Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41:1495-1508.
9. Navab M, Van Lenten BJ, Ansell BJ, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004; 45:993-1007.
10. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004; 173:1-12.
11. Uittenbogaard A, Shaul PW, Yuhanna IS, et al. High-density lipoprotein prevents oxidized low-density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 2000; 275:11278-11283.
12. Levkau B, Hermann S, Theilmeier G, et al. High-density lipoprotein stimulates myocardial perfusion in vivo. Circulation 2004; 110:3355-3359.
13. Vinals M, Martinez-Gonzalez J, Badimon JJ, Badimon L. HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (COX-2). Arterioscler Thromb Vasc Biol 1997; 17:3481-3488.
14. Yui Y, Aoyama T, Morishita H, et al. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-1 (apo A-1). A novel function of apo A-1. J Clin Invest 1988; 82:803-807.
15. Newton RS, Krause BR. HDL therapy for the acute treatment of atherosclerosis. Atheroscler Suppl 2002; 3:31-38.
16. Navab M, Hama S, Hough G, Fogelman A. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice. Circulation 2003; 108:1735-1739.
17. Franceschini G, Sirtori CR, Capurso A II, et al. A-Imilano apoprotein. Decreased high- density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980; 66:892-900.
18. Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipoprotein A-I (Milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Potential implications for acute plaque stablization. Circulation 2001; 103:3047-3050.
19. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA 2003; 290:2292-2300.
20. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA 2002; 287:356-359.
21. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes Care 2002; 25:1198-1202.
22. Rosenson RS. New approaches in the intensive management of cardiovascular risk in the metabolic syndrome. Curr Probl Cardiol 2005; 30:241-279.
23. Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002c; 90(suppl):22i-29i.
24. Rosenson RS, Freedman DS, Otvos JD. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) Trial. Am J Cardiol 2002; 90:89-94.
25. Kuller L, Arnold A, Tracey R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2002; 22:1175-1180.
26. Blake GJ, Otvos JD, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002; 106: 1930-1937.
27. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108:2751-2756.
28. Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-1 trial. Atherosclerosis 2002a; 160:41-48.
29. Blake GJ, Albert MA, Rifai N, Ridker PM. Effect of pravastatin on LDL particle concentration as determined by NMR spectoscopy: a substudy of a randomized placebo controlled trial. Eur Heart J 2003; 24:1843-1847.
30. McKenney JM, McCormick LS, Schaefer EJ, et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 2001; 88:270-274.
31. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004; 24:490-497.
32. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholestreyl ester transfer protein on HDL cholestrol. N Engl J Med 2004; 350:1505-1515.
33. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622.
34. Gotto AM, Whitney E, Stein EH, et al. Relation between baseline and on-treatment lipid parameters and first accurate major coronary atherosclerosis prevention study (AFCAPS/TexCAPS). Circulation 2000; 101:477-484.
35. Rosenson RS. Low HDL and cardiovascular disease: risk reduction with statin therapy. Am Heart J 2005. (in press).
36. Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104:3046-3051.
37. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623-1630.
38. Sacks FM, Tonkin AM, Shepard J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project. Circulation 2000; 102:1893-1900.
39. Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002; 105:1162-1169.
40. Olsson AG, et al. High density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005; 26:890-896.
41. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozii for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-418.
42. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285:1585-1591.
43. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583-1592.
44. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512-3517. Randomized trial that investigated the effects of extended-release niacin on carotid atherosclerosis in statin-treated patients with low normal (<40 mg/dL) HDL cholesterol levels. At 12 months of therapy, rates of carotid progression were less among niacin-treated versus placebo-treated patients (P = 0.08). This study provides limited evidence that treatment of low-normal HDL cholesterol levels is a feasible secondary target of lipid-lowering therapy.